INS and type 2 diabetes mellitus: Previous trials investigating the use of this technology for the management of both type 1 and type 2 diabetes have focused on those requiring intensive insulin therapy using multiple daily injections or continuous subcutaneous insulin infusion.1–6 With increasing access to CGM technology, there is interest in understanding the utility of CGM for improving glycemic control in patients not requiring intensive insulin therapy.